Aeglea BioTherapeutics, Inc. Contracts & Agreements

Underwriting Agreement, by and among the Company and (Filed With SEC on November 19, 2024)

Fifth Amendment to the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan (Filed With SEC on November 7, 2024)

Offer Letter, dated September 20, 2024, by and between the Company and Sheldon Sloan (Filed With SEC on November 7, 2024)

IL-23 (SPY003) License Agreement, dated October 11, 2024, by and between the Company and Paragon Therapeutics, Inc (Filed With SEC on October 15, 2024)

Amended and Restated Biologics Master Services Agreement, dated October 14, 2024, by and between the Company and WuXi Biologics (Hong Kong) Limited (Filed With SEC on October 15, 2024)

Amended and Restated Cell Line License Agreement, dated October 14, 2024, by and between the Company and WuXi Biologics (Hong Kong) Limited (Filed With SEC on October 15, 2024)

47 (SPY001) License Agreement, dated May 14, 2024, by and between the Company and Paragon Therapeutics, Inc (Filed With SEC on August 7, 2024)

TL1A (SPY002) License Agreement, dated May 14 2024, by and between the Company and Paragon Therapeutics, Inc (Filed With SEC on August 7, 2024)

Second Amended and Restated Antibody Discovery and Option Agreement, dated May 14, 2024, by and between the Company, Paragon Therapeutics, Inc. and Parapyre Holding LLC (Filed With SEC on August 7, 2024)

Form of Stock Option Agreement under the Amended and Restated Spyre Therapeutics, Inc. 2016 Equity Incentive Plan (Filed With SEC on August 7, 2024)

Form of Restricted Stock Unit Award Agreement under the Amended Spyre Therapeutics, Inc. 2018 Equity Inducement Plan (Filed With SEC on August 7, 2024)

Form of Warrant to Purchase Common Stock (Parapyre Warrant 2023) (Filed With SEC on May 9, 2024)

Amendment No. 1 to (Filed With SEC on May 9, 2024)

Exchange Agreement, dated April 23, 2024, by and between the Company and Fairmount Healthcare Fund II L.P (Filed With SEC on April 25, 2024)

Securities Purchase Agreement, dated as of March 18, 2024, by and among Spyre Therapeutics, Inc. and each purchaser identified on Annex A thereto (Filed With SEC on March 18, 2024)

Form of Registration Rights Agreement (Filed With SEC on March 18, 2024)

Spyre Therapeutics, Inc. 2016 Employee Stock Purchase Plan, as amended by the First Amendment on January 31, 2024 (Filed With SEC on March 1, 2024)

Offer Letter, dated August 18, 2023, by and between the Company and Heidy King-Jones (Filed With SEC on March 1, 2024)

Consulting Agreement by and between the Company and Mark McKenna, effective August 1, 2023 (Filed With SEC on March 1, 2024)

Description of the Registrant's securities (Filed With SEC on February 29, 2024)

Spyre Therapeutics, Inc (Filed With SEC on February 29, 2024)

Offer Letter, dated August 1 (Filed With SEC on February 29, 2024)

Consulting Agreement by and between the Company and Mark McKenna, effective August 1, 2023 (Filed With SEC on February 29, 2024)

Form of Indemnification Agreement (Filed With SEC on February 5, 2024)

Amendment to the Amended and Restated Letter Agreement by and between the Company and Cameron Turtle, dated as of February 1, 2024 (Filed With SEC on February 5, 2024)

Amended and Restated Offer Letter, dated November 22, 2023 and as amended on February 1, 2024, by and between the Company and Cameron Turtle (Filed With SEC on February 5, 2024)

2024 Form of Indemnification Agreement (Filed With SEC on February 5, 2024)

Agreement and Plan of Merger, dated June 22, 2023, by and among the Company, Aspen Merger Sub I, Inc., Sequoia Merger Sub II, LLC and Spyre Therapeutics, Inc (Filed With SEC on December 22, 2023)

Form of Registration Rights Agreement (December 2023 PIPE) (Filed With SEC on December 22, 2023)

Form of Common Stock Certificate (Filed With SEC on December 22, 2023)

Securities Purchase Agreement, dated December 7, 2023, by and among Spyre Therapeutics, Inc. and each purchaser identified on Annex A thereto (Filed With SEC on December 22, 2023)

Form of Registration Rights Agreement, by and among the Company and certain purchasers (June 2023 PIPE) (Filed With SEC on December 22, 2023)

Form of Pre-Funded Warrants 2022 (Filed With SEC on December 22, 2023)

Biologics Master Services Agreement, effective June 20, 2022, by and between Paragon Therapeutics, Inc. and WuXi Biologics (Hong Kong) Limited (Filed With SEC on December 22, 2023)

Cell Line License Agreement, effective June 20, 2022, by and between Paragon Therapeutics, Inc. and WuXi Biologics (Hong Kong) Limited (Filed With SEC on December 22, 2023)

Novation Agreement, dated September 19, 2023, by and between Paragon Therapeutics, Inc., the Company and WuXi Biologics (Hong Kong) Limited (Filed With SEC on December 22, 2023)

Amended and Restated Offer Letter, dated November 22, 2023, by and between the Company and Cameron Turtle (Filed With SEC on December 22, 2023)

Amended and Restated Antibody Discovery and Option agreement, dated September 29, 2023, by and between Paragon Therapeutics, Inc., Parapyre Holding LLC and Spyre Therapeutics, LLC (Filed With SEC on December 22, 2023)

Form of Amended and Restated Indemnification Agreement (Filed With SEC on December 22, 2023)

2015 Equity Incentive Plan and forms of award agreements (Filed With SEC on December 22, 2023)

Spyre Therapeutics, Inc. 2016 Equity Incentive Plan, As Amended and Restated Effective November 21, 2023 (Filed With SEC on December 22, 2023)

2016 Employee Stock Purchase Plan and forms of award agreements, as amended (Filed With SEC on December 22, 2023)

Spyre Therapeutics, Inc. 2018 Equity Inducement Plan and the First Amendment, Second Amendment, Third Amendment and Fourth Amendment thereto (Filed With SEC on December 22, 2023)

Form of Stock Option Agreement under the Amended and Restated 2018 Equity Inducement Plan (Filed With SEC on December 22, 2023)

Spyre Therapeutics, Inc. 2023 Equity Incentive Plan (Filed With SEC on December 22, 2023)

Form of Stock Restriction Agreement (Filed With SEC on December 22, 2023)

Form of Severance Agreement (Filed With SEC on December 22, 2023)

Separation and Consulting Agreement and General Release of Claims by and between the Company and Jonathan Alspaugh, dated as of September 22, 2023 (Filed With SEC on December 22, 2023)

Offer Letter, dated August 10, 2023, by and between the Company and Scott Burrows (Filed With SEC on December 22, 2023)

Asset Purchase Agreement, dated July 27, 2023, by and between the Company and Immedica Pharma AB (Filed With SEC on December 22, 2023)

Lease Termination Agreement dated August 7, 2023, between the Company and Las Cimas Owner LP (Filed With SEC on December 22, 2023)

Securities Purchase Agreement, dated as of December 7, 2023, by and among Spyre Therapeutics, Inc. and each purchaser identified on Annex A thereto (Filed With SEC on December 8, 2023)

Form of Registration Rights Agreement (Filed With SEC on December 8, 2023)

Amended and restated letter agreement by and between the Company and Cameron Turtle, dated as of November 22, 2023 (Filed With SEC on November 28, 2023)

Agreement and Plan of Merger, dated June 22, 2023, by and among Aeglea BioTherapeutics, Inc. Aspen Merger Sub I, Inc., Sequoia Merger Sub II, LLC and Spyre Therapeutics, Inc (Filed With SEC on November 15, 2023)

Securities Purchase Agreement, dated June 22, 2023, by and among the Registrant and the purchasers named therein (Filed With SEC on November 15, 2023)

Form of Common Stock Certificate (Filed With SEC on November 15, 2023)

Registration Rights Agreement, dated March 16, 2021, by and among the Registrant and Baker Brothers Life Sciences, L.P. and 667, L.P (Filed With SEC on November 15, 2023)

Form of Registration Rights Agreement, by and among Aeglea BioTherapeutics, Inc. and certain purchasers (Filed With SEC on November 15, 2023)

Form of Pre-Funded Warrants 2022 (Filed With SEC on November 15, 2023)

Offer Letter, dated June 22, 2023, by and between Aeglea BioTherapeutics, Inc. and Cameron Turtle (Filed With SEC on November 15, 2023)

Form of Amended and Restated Indemnification Agreement (Filed With SEC on November 15, 2023)

2015 Equity Incentive Plan and forms of award agreements (Filed With SEC on November 15, 2023)

2016 Equity Incentive Plan and forms of award agreements, as amended (Filed With SEC on November 15, 2023)

First Amendment to the Aeglea BioTherapeutics, Inc. 2016 Equity Incentive Plan (Filed With SEC on November 15, 2023)

2016 Employee Stock Purchase Plan and forms of award agreements, as amended (Filed With SEC on November 15, 2023)

2018 Equity Inducement Plan (Filed With SEC on November 15, 2023)

First Amendment to the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan (Filed With SEC on November 15, 2023)

Third Amendment to the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan (Filed With SEC on November 15, 2023)

Form of Stock Option Agreement under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan (Filed With SEC on November 15, 2023)

Amended and Restated Spyre 2023 Equity Incentive Plan (Filed With SEC on November 15, 2023)

Form of Stock Restriction Agreement (Filed With SEC on November 15, 2023)

Form of Severance Agreement (Filed With SEC on November 15, 2023)

Separation and Consulting Agreement and General Release of Claims by and between the Company and Jonathan Alspaugh, dated as of September 22, 2023 (Filed With SEC on November 15, 2023)

Offer Letter, dated August 10, 2023, by and between the Company and Scott Burrows (Filed With SEC on November 15, 2023)

Asset Purchase Agreement, dated July 27, 2023, by and between Aeglea BioTherapeutics, Inc. and Immedica Pharma AB (Filed With SEC on November 15, 2023)

Biologics Master Services Agreement, effective June 20, 2022, by and between Paragon Therapeutics, Inc. and WuXi Biologics (Hong Kong) Limited (Filed With SEC on October 10, 2023)

Cell Line License Agreement, effective June 20, 2022, by and between Paragon Therapeutics, Inc. and WuXi Biologics (Hong Kong) Limited (Filed With SEC on October 10, 2023)

Novation Agreement, dated September 19, 2023, by and between Paragon Therapeutics, Inc., Aeglea BioTherapeutics, Inc. and WuXi Biologics (Hong Kong) Limited (Filed With SEC on October 10, 2023)

Amended and Restated Antibody Discovery and Option agreement, dated September 29, 2023, by and between Paragon Therapeutics, Inc., Parapyre Holding LLC and Spyre Therapeutics, LLC (Filed With SEC on October 10, 2023)

Second Amendment to the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan (Filed With SEC on October 10, 2023)

Lease Termination Agreement dated August 7, 2023, between Aeglea BioTherapeutics, Inc. and Las Cimas Owner LP (Filed With SEC on October 10, 2023)

Separation and Consulting Agreement and General Release of Claims by and between the Company and Jonathan Alspaugh, dated as of September 22, 2023 (Filed With SEC on September 25, 2023)

Offer Letter by and between the Company and Scott Burrows, dated as of August 10, 2023 (Filed With SEC on September 5, 2023)

Offer Letter, dated June 22, 2023, by and between Aeglea BioTherapeutics, Inc. and Cameron Turtle (Filed With SEC on August 11, 2023)

Antibody Discovery and Option agreement, dated May 25, 2023, by and between Paragon Therapeutics, Inc., Parapyre Holding LLC and Spyre Therapeutics, Inc (Filed With SEC on August 11, 2023)

First Amendment to the Aeglea BioTherapeutics, Inc. 2016 Equity Incentive Plan (Filed With SEC on August 11, 2023)

First Amendment to the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan (Filed With SEC on August 11, 2023)

Amended and Restated Spyre 2023 Equity Incentive Plan (Filed With SEC on August 11, 2023)

Form of Stock Option Agreement under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan (Filed With SEC on August 11, 2023)

Asset Purchase Agreement, dated July 27, 2023, by and between Aeglea BioTherapeutics, Inc. and Immedica Pharma AB (Filed With SEC on August 11, 2023)

Agreement and Plan of Merger, dated June 22, 2023, by and among Aeglea BioTherapeutics, Inc. Aspen Merger Sub I, Inc., Sequoia Merger Sub II, LLC and Spyre Therapeutics, Inc (Filed With SEC on June 23, 2023)

Securities Purchase Agreement, dated as of June 22, 2023, by and among Aeglea BioTherapeutics, Inc. and each purchaser identified on Annex A thereto (Filed With SEC on June 23, 2023)

Form of Registration Rights Agreement, by and among Aeglea BioTherapeutics, Inc. and certain purchasers (Filed With SEC on June 23, 2023)

Capital on DemandTM Sales Agreement, dated May 20, 2022, by and between Aeglea BioTherapeutics, Inc. and JonesTrading Institutional Services LLC (Filed With SEC on May 20, 2022)

Form of Pre-Funded Warrant (Filed With SEC on May 6, 2022)

Form of Securities Purchase Agreement, dated as of May 5, 2022, by and among Aeglea BioTherapeutics, Inc. and the purchasers identified therein (Filed With SEC on May 6, 2022)

Offer Letter, dated June 14, 2021 issued by the Registrant to Mr. Jonathan Alspaugh (Filed With SEC on March 8, 2022)

Severance Agreement dated July 6, 2021 by and between the Registrant and Mr. Jonathan Alspaugh (Filed With SEC on March 8, 2022)

License and Supply Agreement, dated March 21, 2021, by and between the Registrant and Immedica Pharma AB (Filed With SEC on May 10, 2021)

Description of the Registrant's securities (Filed With SEC on March 18, 2021)

Registration Rights Agreement, dated March 16, 2021, by and among the Registrant and Baker Brothers Life Sciences, L.P. and 667, L.P (Filed With SEC on March 18, 2021)

Offer letter, dated March 13, 2020 issued by the Registrant to Dr. Leslie Sloan (Filed With SEC on May 7, 2020)

Severance Agreement dated August 7, 2019 by and between the Registrant and Dr. Leslie Sloan (Filed With SEC on May 7, 2020)

Underwriting Agreement dated April 28, 2020 (Filed With SEC on April 28, 2020)

Form of Pre-Funded Warrant (Filed With SEC on April 28, 2020)

Capital on DemandTM Sales Agreement, dated April 16, 2020, by and between Aeglea BioTherapeutics, Inc. and JonesTrading Institutional Services LLC (Filed With SEC on April 16, 2020)

Description of the Registrant's securities (Filed With SEC on February 24, 2020)

Lease Agreement, dated April 30, 2019, between Las Cimas Owner LP and the Registrant (Filed With SEC on May 7, 2019)

Amendment #1, dated December 4, 2018, to Amendment and Restated Investors' Rights Agreement, as amended (Filed With SEC on March 7, 2019)

2016 Employee Stock Purchase Plan and forms of award agreements, as amended (Filed With SEC on March 7, 2019)

Amended and Restated Patent License Agreement No. PM1401501, dated January 31, 2017, between the Registrant and The University of Texas at Austin on behalf of the Board of Regents... (Filed With SEC on March 7, 2019)

Master Services Agreement, dated November 26, 2018, between the Registrant, Fujifilm Diosynth Biotechnologies UK Limited, Fujifilm Diosynth Biotechnologies Texas, LLC, and... (Filed With SEC on March 7, 2019)

Underwriting Agreement dated February 5, 2019, as amended (Filed With SEC on February 7, 2019)

Form of Pre-Funded Warrant (Filed With SEC on February 7, 2019)

Amended and Restated 2016 Equity Incentive Plan (Filed With SEC on November 8, 2018)

Form of Amended and Restated Indemnification Agreement (Filed With SEC on August 9, 2018)

Offer Letter, dated July 18, 2018 by and between the Company and Anthony G. Quinn (Filed With SEC on July 23, 2018)

Severance Agreement, dated July 18, 2018 by and between the Company and Anthony G. Quinn (Filed With SEC on July 23, 2018)

Underwriting Agreement dated April 18, 2018 (Filed With SEC on April 19, 2018)

Form of Severance Agreement (Filed With SEC on April 16, 2018)

Amended and Restated Patent License Agreement No. PM1401501, dated January 31, 2017, between the Registrant and The University of Texas at Austin on behalf of the Board of Regents... (Filed With SEC on March 13, 2018)

Offer Letter, dated June 20, 2017, issued by the Registrant to Dr. James Wooldridge (Filed With SEC on March 13, 2018)

Offer Letter, dated August 31, 2017, issued by the Registrant to Dr. Anthony Quinn (Filed With SEC on November 7, 2017)

Sponsored Research Agreement No. UTA13-001113, dated December 24, 2013, between The University of Texas at Austin and Aeglea BioTherapeutics, Inc., Aeglea Development Company,... (Filed With SEC on November 7, 2017)

Terms of Resignation between the Registrant and Dr. David G. Lowe (Filed With SEC on August 9, 2017)

UNDERWRITING AGREEMENT 3,000,000Shares AEGLEA BIOTHERAPEUTICS, INC. Common Stock ($0.0001 Par Value) EQUITY UNDERWRITING AGREEMENT (Filed With SEC on June 6, 2017)

Offer Letter, dated April 21, 2017, issued by the Registrant to Dr. Anthony Quinn (Filed With SEC on May 9, 2017)

Amended and Restated Patent License Agreement Agreement No. PM1401501 (Filed With SEC on March 23, 2017)

Exhibit a (Filed With SEC on March 23, 2017)

Vice President of Finance Severance Agreement (Filed With SEC on March 23, 2017)

FIRST AMENDMENT TO OFFICE LEASE AND ASSIGNMENT AND ASSUMPTION OF LEASE (Filed With SEC on November 9, 2016)

SPONSORED RESEARCH AGREEMENT NO. UTA13-001113 (Filed With SEC on November 9, 2016)

[ ] Shares Aeglea BioTherapeutics, Inc. COMMON STOCK UNDERWRITING AGREEMENT (Filed With SEC on March 28, 2016)

AEGLEA BIOTHERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN (Filed With SEC on March 28, 2016)

AEGLEA BIOTHERAPEUTICS, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on March 28, 2016)

SPONSORED RESEARCH AGREEMENT NO. UTA13-001113 (Filed With SEC on March 14, 2016)

VICE PRESIDENT SEVERANCE AGREEMENT (Filed With SEC on March 14, 2016)

SPONSORED RESEARCH AGREEMENT NO. UTA13-001113 (Filed With SEC on November 5, 2015)

Additional abbreviations may also be used though not in the above list. FOR VALUE RECEIVED, hereby sell(s), assign(s) and transfer(s) unto (Filed With SEC on September 14, 2015)

INDEMNITY AGREEMENT (Filed With SEC on September 14, 2015)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on September 14, 2015)

SPONSORED RESEARCH AGREEMENT NO. UTA13-001113 (Filed With SEC on September 14, 2015)

Master Services Agreement (Filed With SEC on September 14, 2015)

PATENT LICENSE AGREEMENT AGREEMENT NO. PM1401601 (Filed With SEC on September 14, 2015)

CEO SERVERANCE AGREEMENT (Filed With SEC on September 14, 2015)

VICE PRESIDENT SEVERANCE AGREEMENT (Filed With SEC on September 14, 2015)

AEGLEA BIOTHERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT March 10, 2015 TABLE OF CONTENTS (Filed With SEC on June 16, 2015)

AEGLEA BIOTHERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN As Adopted on March 10, 2015 (Filed With SEC on June 16, 2015)

AEGLEA BIOTHERAPEUTICS, INC. STOCK RESTRICTION AGREEMENT (Filed With SEC on June 16, 2015)

SPONSORED RESEARCH AGREEMENT NO. UTA13-001113 (Filed With SEC on June 16, 2015)

Master Services Agreement (Filed With SEC on June 16, 2015)

OFFICELEASE BETWEEN BARTON OAKS OFFICE CENTER, LLC (LANDLORD) AND AEGLEA DEVELOPMENTCOMPANY, INC. (TENANT) TABLE OF CONTENTS (Filed With SEC on June 16, 2015)

CONSULTING AGREEMENT (Filed With SEC on June 16, 2015)

PATENT LICENSE AGREEMENT AGREEMENT NO. PM1401601 (Filed With SEC on June 16, 2015)

aegleabio.com Aeglea Biotherapeutics 901 MoPac Expressway South, Suite 250, Austin, TX 78746 ###-###-#### (Filed With SEC on June 16, 2015)

Category

Industry

Companies

Contracts

Aeglea BioTherapeutics, Inc. Contracts & Agreements